{"id":303020,"date":"2024-12-27T15:08:00","date_gmt":"2024-12-27T15:08:00","guid":{"rendered":"http:\/\/www.cheln.com\/index.php\/2024\/12\/27\/2354c9bd1b9fe37a5385e7b825ca5a1f"},"modified":"2024-12-27T15:08:00","modified_gmt":"2024-12-27T15:08:00","slug":"2354c9bd1b9fe37a5385e7b825ca5a1f","status":"publish","type":"post","link":"http:\/\/www.cheln.com\/index.php\/2024\/12\/27\/2354c9bd1b9fe37a5385e7b825ca5a1f\/","title":{"rendered":"Takeda Announces Approval of HYQVIA\u00ae 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
"},"content":{"rendered":"
\"\u9996\u5716\" OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502\/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVI…<\/div>\n